Edward A. Sausville

University of Maryland, Baltimore — United States

Medicine · Health Sciences

101h-index39.6kcitations484works3.72yr avg
OpenAlex↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cancer-related Molecular Pathways(63), Cancer therapeutics and mechanisms(54), Cancer Treatment and Pharmacology(46), Chronic Lymphocytic Leukemia Research(34), Chronic Myeloid Leukemia Treatments(28)

Publications479 total

Results of an Integrated Phase I/II Prospective Clinical Trial (NEXIS) for Neoadjuvant Anti-PD-L1 (Durvalumab) and Anti-CTLA-4 (Tremelimumab) With Radiation for High-Risk Soft-Tissue Sarcoma of the Trunk and Extremities
Cureus·2024· 1 citedOpen Access
Editor's Note: Antiangiogenic Properties of 17-(Dimethylaminoethylamino)-17-Demethoxygeldanamycin: An Orally Bioavailable Heat Shock Protein 90 Modulator
Clinical Cancer Research·2024Open Access
Phase 1 trial of navitoclax and sorafenib in patients with relapsed or refractory solid tumors with hepatocellular carcinoma expansion cohort
Investigational New Drugs·2024· 10 cited
Drug Development in Oncology
2023· 1 citedOpen Access
Antimitotics
2023
Cancer Pharmacology
2023· 1 cited
Alkylating Agents and Drugs Perturbing DNA Structure
2023
Replacement of Antiretroviral Therapy with HIV Broadly Neutralizing Antibodies to Maximize the Effectiveness of Chemotherapy in HIV Patients with Lung Cancer
AIDS Research and Human Retroviruses·2023Open Access
Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Data from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Table 2 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figures S1-S3 from Preclinical Studies of Vorinostat (Suberoylanilide Hydroxamic Acid) Combined with Cytosine Arabinoside and Etoposide for Treatment of Acute Leukemias
2023Open Access
Supplementary Table 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 4 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure 1 from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Figure Legends from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
Supplementary Methods from Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor Veliparib (ABT-888) in Combination with Irinotecan in Patients with Advanced Solid Tumors
2023Open Access
page 1 of 24Next →

Frequent Co-authors

Adrian M. Senderowicz(9), Peter J. Worland(8), Dominic A. Scudiero(5), Daniel Zaharevitz(4), Susan G. Arbuck(4), Melinda G. Hollingshead(4), William D. Figg(4), Kurt W. Kohn(3), Timothy G. Myers(3), John N. Weinstein(3), P M O'Connor(3), Donna Headlee(3), Sherman F. Stinson(3), Gurmeet Kaur(3), J. Peisach(3), Susan Band Horwitz(3), Julian Adams(2), J I Johnson(2), Peter J. Elliott(2), Stephen Friend(2)